Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 16/20 | 0.67 |
| ▸ | CBFB | Q13951 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292330 | 0.92 | GCK (0.66) | GCKCBFB | |
| SCHEMBL2291624 | 0.89 | GCK (0.66) | GCKCBFB | |
| SCHEMBL1656437 | 0.88 | GCK (0.70) | GCKCBFB | |
| SCHEMBL2294667 | 0.87 | GCK (0.64) | GCKCBFB | |
| SCHEMBL12730498 | 0.86 | GCK (0.67) | GCKCBFBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1656346 | 0.86 | GCK (0.71) | GCKCBFBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1659191 | 0.85 | GCK (0.75) | GCKCBFB | |
| SCHEMBL15158259 | 0.84 | GCK (0.69) | GCKCBFB | |
| SCHEMBL5071857 | 0.83 | GCK (0.78) | GCK | |
| SCHEMBL1659496 | 0.83 | GCK (0.72) | GCKCBFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1905769-B1 | HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-7994331-B2 | Heterocycle-substituted benzimidazole derivative | MSD K.K. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100087360-A1 | Heterocycle-substituted benzimidazole derivative | MSD K.K. (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1905769-A1 | HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087360-A1 | Heterocycle-substituted benzimidazole derivative | GCK, GCKR, HK1 | GCK 1/4885CBFB 2061/4885CYP1A2 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.